Page 25 - MEMOCiberehd014-ENG

P3. CHOLESTASIS, METABOLIC DISORDERS AND HEPATOTOXICITY
Coordinator:
Dr. Juan F. Medina
Associate Coordinators: Drs. Albert Parés and José Carlos Fernández-Checa
Description
Program 3 includes ten groups, the research activities of which are mainly related to cholestasis, metabolic disorders and hepatotoxicity . The groups led by Dr . Albert Parés, Dr . Llorenç Caballería, and Dr . Juan F . Medina are focusing on clinical, epidemiological and basic studies of cholestatic diseases, such as primary biliary cirrhosis and other chronic cholestatic conditions . As regards the basic aspects, the study of impairments in the transport of various components of bile, as well as the etiopathogenesis of osteopenia associated with cholestatic syndromes stand out . The other seven groups from the program develop their research on metabolic disorders and more specifically, the study of steatohepatitis and liver toxicity . Therefore, these groups conduct studies related to the mechanisms of oxidative stress and apoptosis in hepatocytes, as well as the role of cytokines and adipocytokines in metabolic, toxicological and infectious liver disorders . Highly relevant in this regard are the activities carried out by Dr . José M . Mato and Dr . José C . Fernández-Checa’s groups, which have been awarded a substantial number of projects and carry out multiple collaborations with other groups . In this regard, the grant of the INTERCIBER Project Understanding obesity (Ob), metabolic syndrome (MetS), type 2 diabetes (T2DM) and fatty liver disease (FL): a multidisciplinary approach, should be highlighted . This project is led by CIBEREHD (particularly Dr . José M . Mato and Dr . Ma Luz Martínez-Chantar) and three other CIBERs actively participate in it within the subject Areas of Obesity and Nutrition (Ciberobn), Diabetes and Associated Metabolic Diseases (Ciberdem) and Mental Health (Cibersam) . Moreover, the groups led by Dr . Javier González Gallego and Dr . Carmelo García Monzón and Dr . Paloma Martín Sanz maintain a close collaboration for the study of antioxidant therapies in models of hepatitis C . Finally, the groups led by Dr . Jose V . Castell and Dr . Raúl Andrade are working closely with one another and with the preceding groups in researching different molecular mechanisms that cause hepatotoxicity .
Program Projects and Collaborations
The groups that form Program 3 maintain collaborative networks with more than 25 groups with one another (intra-nodal collaborations) and with other external groups (inter-nodal collaborations) . Dr . José M . Mato’s group, from CIC BioGUNE, continues to significantly potentiate these collaborations through its Genomics, Proteomics, Metabolomics and Gene Silencing Platforms, which are also available to all CIBEREHD groups . Also, collaborations based on these platforms continue to be consolidated through the organisation of classroom sessions and other training activities .
Additionally, several high-impact publications further show the high quality of current collaborations, as illustrated by the following examples:
Fucho r, Martínez l, baulies a, torres s, tarrats n, FernanDez a, ribas v, astuDillo aM, balsinDe J, Garcia- rovés P, elena M, berGheiM i, lotersztaJn s, trautwein c, aPPelqvist h, Paton aw, Paton Jc, czaJa MJ, KaPlowitz n, FernanDez-checa Jc, García-ruiz c. ASMase regulates autophagy and lysosomal membra- ne permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis . J Hepatol 2014;61:1126-1134 . (IF 2013: 10 .401)
aFFò s, Morales-ibanez o, roDriGo-torres D, altaMirano J, blaya D, DaPito Dh, Millán c, coll M, caviGlia JM, arroyo v, caballería J, schwabe rF, Ginès P, bataller r, sancho-bru P. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis . Gut 2014;63:1782-92 . (IF 2013: 13 .319)
www .ciberehd .org 25